SGLT 2 INHIBITORS | Latest News RSS feed

SGLT 2 INHIBITORS - Latest News


Amazing Outcomes with Combination Therapy of GLP-1 Receptor Agonist and SGLT2 Inhibitors

Combination therapy of GLP-1 RAs and SGLT2is: different MOAs of these drugs make them an excellent combination in treating patients with type 2 diabetes mellitus (T2DM). The Ominous Octet is the combination of at least eight pathophysiologic abnormalities ... read more

Ertugliflozin for type 2 diabetes

Like the three other sodium-glucose co-transporter 2 (SGLT2) inhibitors sanctioned before it, the drug works by regulating renal glucose reabsorption and stimulating urinary glucose excretion. As a result, it effectively reduces blood glucose levels ... read more

Lexicon Pharmaceuticals to Present New Clinical Data at 78th American Diabetes Association Scientific Sessions

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1) (#212-OR) Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an ... read more

Looking for another news?


New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

INDIANAPOLIS, Feb. 26, 2018 /PRNewswire/ -- Trulicity ® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor ... read more

WordPress.com

New Data Show Lilly's Trulicity® (dulaglutide) in Combination wi - KPTV - FOX 12

INDIANAPOLIS, Feb. 26, 2018 /PRNewswire/ -- Trulicity ® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor ... read more

SGLT-2 inhibitors cut risk of death in diabetics, data shows

AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 inhibitors. The real-world evidence study is evaluating the ... read more

Risk of Euglycemic Diabetic Ketoacidosis After Initiation of an SGLT-2 Inhibitor

Detection of euglycemic diabetic ketoacidosis could be a challenge for physicians since this condition can mask an underlying diabetic ketoacidosis. Using the database of Therapeutic Goods Administration (TGA) of the Australian Government Department of ... read more

BRIEF-FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes

Dec 22 (Reuters) - Merck & Co Inc: * FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES * MERCK & CO INC - FDA APPROVED STEGLATRO TABLETS, AN ... read more

New data show Lilly's Trulicity in combination with an SGLT-2 inhibitor improves blood sugar control in type 2 diabetics

Eli Lilly and Company (NYSE:LLY) announces that Trulicity (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor ... read more

BRIEF-FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes

Dec 22 (Reuters) - Merck & Co Inc: * FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES * MERCK & CO INC - FDA APPROVED STEGLATRO TABLETS, AN ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us